Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug
The S&P 500 index has recently fallen below its crucial 50-day moving average, a technical event that is sending ripples of concern throughout global financial markets. This breach, occurring as of November 7, 2025, is widely interpreted by analysts and investors as a significant bearish signal, indicating a potential
Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto markets.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Moderna's Q3 2025 earnings beat revenue estimates with $1.016B and a narrower loss. Shares rose on strong COVID vaccine sales and an improved 2025 financial outlook.
Washington D.C., November 5, 2025 – The U.S. services sector has delivered a powerful jolt of optimism to financial markets, with robust Purchasing Managers' Index (PMI) data for October 2025 largely dispelling lingering economic worries and significantly contributing to the U.S. stock market's positive returns. Both the S&
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
